Live Med
  • Live
  • On Demand
    • Congresses
    • Web Events
  • Public
  • Specialty
    • Child Psychiatry
    • Dermatology
    • Forensic Medicine
    • Gynecology
    • Haematology
    • Medical Oncology
    • Neurology
    • Ophthalmology
    • Paediatric
    • Pathology
    • Pulmonology
    • Radiation Oncology
    • Rheumatology
    • Surgery
    • Surgical Oncology
    • Urology
    • Angiosurgery
    • Radiology
    • Allergology
    • Anesthesiology
    • Gastroenterology
    • General Medicine
    • Endocrinology
    • Medical Work
    • Cardiology
    • Social Medicine
    • Cytology
    • Microbiology (Medical Biopathology)
    • Neurosurgery
    • Nephrology
    • Orthopedics
    • Pathology Anatomy
    • Plastic Surgery
    • Nuclear Medicine
    • Physical Medicine and Rehabilitation
    • Thoracic Surgery
    • Children Surgery
    • Psychiatry
    • Otorhinolaryngology
  • Studio
  • Contact Us
  • ABOUT US
  • Support Q&A

LOG IN
REGISTER
LOG INREGISTER

  • EN
  • EL
  • Home
  • Categories
  • 18-01-2020
Go Back
Go Back

18-01-2020

37 D. Rimm - Analytic approaches to understanding PD-L1 expression and mechanism of action.

37 D. Rimm - Analytic approaches to understanding PD-L1 expr...

38 N. Normanno - Liquid biopsies: facts and myths.

38 N. Normanno - Liquid biopsies: facts and myths.

39 F. Hirsch - Next Generation Sequencing: is there any clinical use?

39 F. Hirsch - Next Generation Sequencing: is there any clin...

40 G. Bronte - Mechanisms of acquired resistance to EGFR TKIs.

40 G. Bronte - Mechanisms of acquired resistance to EGFR TKI...

41 Discussion

41 Discussion

42 L. Landi - Current treatment algorithms for EGFR-mutated patients.

42 L. Landi - Current treatment algorithms for EGFR-mutated...

43 B. Oyan-Uluc - Current treatment algorithms for ROS1+ patients.

43 B. Oyan-Uluc - Current treatment algorithms for ROS1+ pat...

44 V. Papadimitrakopoulou - Targeted therapy beyond EGFR, ALK and ROS1.

44 V. Papadimitrakopoulou - Targeted therapy beyond EGFR, AL...

45 Discussion

45 Discussion

46 E. Linardou - Lorlatinib in ALK+ NSCLC: the next step.

46 E. Linardou - Lorlatinib in ALK+ NSCLC: the next step.

47 S. Agelaki - Immunotherapy in 1st line NSCLC: from trials to practice.

47 S. Agelaki - Immunotherapy in 1st line NSCLC: from trials...

48 F. Grossi - I O combination in 1st line NSCLC - practice changing?

48 F. Grossi - I O combination in 1st line NSCLC - practice...

49 S. Gettinger  - Immunotherapy in oncogene driven mNSCLC.

49 S. Gettinger - Immunotherapy in oncogene driven mNSCLC.

50 D. Rimm - Immunotherapy biomarkers beyond PD-L1.

50 D. Rimm - Immunotherapy biomarkers beyond PD-L1.

51 R. Pirker  - The role of targeted therapies in early stages of NSCLC.

51 R. Pirker - The role of targeted therapies in early stage...

  • Next

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016

livemed white

Λογότυπο Livemed


© 2026 Live Med | Web Design by Ruler Digital Agency & CnC Tech